Login to Your Account

Genmab, J&J in $175M Per Product DuoBody Deal

By Cormac Sheridan
Staff Writer

Wednesday, July 18, 2012
Genmab A/S entered its second DuoBody deal with a large pharmaceutical firm inside two months. The Copenhagen, Denmark-based antibody developer entered a broad collaboration with the Johnson & Johnson subsidiary Janssen Biotech Inc. to develop bispecific antibodies against Janssen-supplied targets.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription